What happened with REPL today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Replimune Group, Inc. is a clinical-stage drug developer with no products approved for sale and no product-sales revenue. It has funded operations mainly by selling shares, supplemented by borrowing, and expects to need additional financing to continue development and prepare for commercialization.
Its candidates use modified viruses injected directly into tumors to treat cancer. All rely on its proprietary RPx platform. RP1’s application for advanced melanoma has received FDA complete response letters rather than approval. Replimune generally tests its candidates alongside other companies’ cancer immunotherapies, so development also depends on access to those drugs, including nivolumab supplied by Bristol Myers Squibb.
Replimune plans to sell approved treatments itself in the United States and potentially work with partners elsewhere. Future sales would depend on physicians adopting the treatments and government and private payors providing coverage and reimbursement. Collaboration or licensing agreements could also bring payments, but Replimune cannot market or sell a candidate before regulatory approval.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Replimune hinges on clinical and regulatory success for its cancer-killing virus therapies and access to combination drugs, including Roche’s atezolizumab and bevacizumab for its liver cancer study.
Iovance Biotherapeutics sells Amtagvi, a one-time treatment made from a patient’s own immune cells, for previously treated advanced melanoma—the patients Replimune targets with its RP1 combination. Amtagvi sales show uptake of an already marketed alternative.
Candel Therapeutics and Replimune both need engineered viral cancer therapies to prove effective and win regulatory acceptance, though their lead programs target different cancers. Watch Candel’s linoserpaturev results in recurrent high-grade glioma for evidence about its herpes simplex virus approach.
Amgen sells T-Vec, a virus therapy injected into melanoma tumors that competes with Replimune’s RP1, and grants Replimune patent rights. Replimune owes Amgen low-single-digit royalties on net sales of products covered by the agreement, assessed country by country and product by product.
IDEAYA Biosciences’ darovasertib regimens compete for uveal melanoma patients with Replimune’s RP2 program, whose trial could support an approval application. Darovasertib’s clinical results are the direct comparison to watch; IDEAYA retains U.S. rights and licenses development and sales outside the United States to Servier.
Immunocore already earns sales from KIMMTRAK in uveal melanoma, where Replimune is developing RP2. Watch KIMMTRAK uptake among its approved patient group: HLA-A*02:01-positive adults with unresectable or metastatic disease.
Delcath Systems sells HEPZATO KIT in the United States for certain adults with unresectable uveal melanoma liver metastases, overlapping patients in Replimune’s RP2 trial. Sales of this treatment, which delivers chemotherapy to the liver while filtering blood to limit exposure elsewhere, show uptake of a liver-directed alternative.
Replimune depends on Bristol Myers Squibb to supply nivolumab for its lead combination trials, even as Bristol Myers Squibb sells melanoma treatments competing for the same indications. Timely, adequate nivolumab supply matters directly to keeping RP1 and RP2 trials running.
CG Oncology offers a read on Replimune’s treatment approach rather than its lead market: both develop viruses that kill cancer cells and stimulate immunity, but CG Oncology targets bladder cancer. Watch cretostimogene’s efficacy and regulatory progress in high- and intermediate-risk non-muscle-invasive bladder cancer.
Replimune relies on Regeneron for cemiplimab used in combination trials, while Regeneron also develops competing cancer immunotherapies. Cemiplimab supply decisions matter more directly to these trials than Regeneron’s broader medicine sales: interruptions could delay or halt development.
Immatics’ anzu-cel cell therapy competes with Replimune’s melanoma immunotherapy programs. Watch anzu-cel’s clinical progress in melanoma; Immatics has also arranged commercial manufacturing supplies for the product.
Agenus’ next-generation CTLA-4 immunotherapies compete with Replimune’s cancer-killing viruses equipped with CTLA-4-directed activity. Watch results for botensilimab alone and with balstilimab; Agenus has begun earning treatment revenue through authorized access programs, which are not marketing approval.
CytomX Therapeutics’ CX-801 competes for metastatic melanoma patients whose disease resists checkpoint inhibitors, a group also targeted by Replimune’s melanoma programs. Watch whether CX-801 demonstrates benefit in those patients, where CytomX says proving efficacy may be challenging.
Merck competes with Replimune’s immunotherapy programs through Keytruda sales for melanoma and development of combination treatments for refractory colorectal cancer.
Calidi Biotherapeutics and Replimune both develop engineered cancer-killing viruses carrying immune-stimulating payloads, but use different delivery platforms and are at different development stages. Watch Calidi’s CLD-401, designed to deliver an IL-15 immune stimulant at tumor sites; its reported systemic-delivery evidence is from animal models.
Fed Interest Rate Decision
The Fed’s decision on its benchmark interest rate can affect the cash interest Replimune pays on its floating-rate Hercules loan, changing cash available for developing its cancer-treatment candidates.
Expected4.0%Last release4.0%
If it comes in above expectations
If the Fed’s policy rate is higher than expected, rising rates across the economy may lift prime and increase the cash interest Replimune pays on its Hercules loan, leaving less cash for candidate development.
If it comes in below expectations
If the Fed’s policy rate is lower than expected, falling rates may ease pressure on prime and reduce the cash interest Replimune pays on its Hercules loan, leaving more cash for candidate development.
Bristol-Myers Squibb Co. earningsBMY
Bristol Myers Squibb’s report will show what its business and product decisions mean for nivolumab, which Replimune relies on to keep certain trials running.
Watch what Bristol Myers Squibb says about nivolumab supply and product decisions. Reliable supply and continued availability for the trials would remove one practical obstacle for Replimune; an interruption or change that limits access could delay or disrupt those trials.
Delcath Systems Inc earningsDCTH
Delcath Systems’ report will show HEPZATO KIT sales and uptake of a liver-directed treatment among patients who overlap with Replimune’s RP2 trial in uveal melanoma that has spread to the liver.
Look for whether HEPZATO KIT sales grow. Growth would show patients and doctors using this available treatment for liver metastases, giving Replimune’s RP2 a clearer alternative to contend with among overlapping patients; weaker sales would indicate limited uptake, not establish RP2’s efficacy.
Replimune Group, Inc. earningsThis company
Replimune has no approved products, so this report will show how much its trials and launch preparations cost and how long its available funds may last.
Read research and development spending and selling, general and administrative costs alongside cash and short-term investments. Slower expense growth and slower cash use would leave more room before Replimune needs financing; faster expense growth and faster cash use would make that need more pressing.
Iovance Biotherapeutics, Inc. earningsIOVA
Iovance Biotherapeutics’ report will show sales of Amtagvi, a marketed alternative for previously treated advanced melanoma patients who also overlap with the group Replimune targets with RP1.
Look for whether Amtagvi sales grow. Growth would show that patients and treatment centers are taking up this available option, making competition for Replimune’s overlapping patients more tangible; weak sales would point to limited uptake, but would not explain why or establish how RP1 works.
